FINWIRES · TerminalLIVE
FINWIRES

Ultragenyx Says Phase 3 Study on Rare Neurogenetic Disorder Missed Primary, Secondary Endpoints; Shares Fall After-Hours

By

Ultragenyx Pharmaceutical (RARE) said late Wednesday the phase 3 Aspire study of apazunersen in Angelman syndrome, a rare, neurogenetic disorder, did not achieve its primary endpoint or its key secondary endpoint.

The late-stage study did not reach the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index, according to a statement.

The safety profile for the phase 3 trial remained consistent with phase 1 and phase 2, the company said.

Ultragenyx said it will assess the apazunersen program following this outcome and make a decision on its disposition.

Shares of Ultragenyx were down about 45% in after-hours trading.

Related Articles

Wire

American Healthcare REIT Closes $572 Million in Initial Kensington Senior Living Acquisitions

American Healthcare REIT (AHR) completed the acquisitions of six Kensington Senior Living communities comprising 464 units for $572 million.Two additional communities are subject to definitive purchase agreements and are expected to close in Q4, subject to conditions, American Healthcare said Tuesday in a statement.The full eight-community portfolio has 745 units with an aggregate contract purchase price of $873 million, the company said. Kensington will continue operating the communities after the closings.The transaction establishes a long-term strategic partnership, American Healthcare said.American Healthcare shares rose 3.6% in after-hours trading.

$AHR
Wire

Gitlab Q2 Adjusted EPS Flat, Revenue Rises; Q3 Guidance Set

Gitlab (GTLB) reported Tuesday Q2 adjusted earnings of $0.24 per diluted share, unchanged from a year earlier.Analysts polled by FactSet expected $0.18.Revenue for the quarter ended July 31 was $286.3 million, up from $236.0 million a year ago.Analysts expected $273.1 million.GitLab expects Q3 adjusted EPS of $0.19 to $0.20 on revenue of $281 million to $283 million. Analysts expect $0.18 and $280.9 million, respectively.For fiscal 2027, the company currently expects adjusted EPS of $0.85 to $0.87 on revenue between $1.129 billion and $1.133 billion. Analysts expect $0.81 and $1.12 billion, respectively.

$GTLB
Wire

Honeywell Aerospace to Pay Over $2 Million in US Defense Contract Settlement, Shares Fall

Honeywell Aerospace (HONA) has agreed to pay over $2 million to settle allegations that it failed to comply with cybersecurity requirements in a US Department of Defense contract, the US Department of Justice said Tuesday.The settlement resolves allegations that, from April 2020 through Dec. 2023, a unit of Honeywell International (HON) submitted false claims for payment after failing to meet cybersecurity requirements for one of Honeywell's networks.Honeywell Aerospace became a standalone company on June 29 after separating from Honeywell International.Shares of Honeywell Aerospace were down 2.4% in late afternoon trading.Price: $154.42, Change: $-3.69, Percent Change: -2.33%

$HON$HONA